文献速递心力衰竭与心肌病

ICD在非缺血性射血分数降低心衰中的长期疗效:DANISH试验延长随访分析

Long-Term Effect of ICDs in Nonischemic Heart Failure With Reduced Ejection Fraction: Extended Follow-Up Analysis of DANISH.
PubMed 文献 · J Am Coll Cardiol · 2025-10-22

DANISH试验延长随访至中位13.2年,纳入1116例非缺血性HFrEF患者,比较ICD与常规治疗。ICD未显著降低全因死亡(HR 0.96),但降低心血管猝死(HR 0.54),且年龄显著影响猝死获益,≤70岁者获益更明显。

要点

  • 非缺血性HFrEF患者中,ICD未显著降低长期全因死亡。
  • ICD显著降低长期心血管猝死风险,HR 0.54。
  • 年龄≤70岁者ICD降低猝死获益显著,>70岁者未见获益。

核心结论

  • 在非缺血性HFrEF患者中,中位随访13.2年,ICD未降低全因死亡,但降低心血管猝死,年轻个体获益更明显。

研究设计与样本

  • DANISH试验延长随访分析,纳入1116例非缺血性HFrEF患者,左室射血分数≤35%,NYHA II-III级(计划CRT者为IV级),利钠肽升高,随访至死亡或2024年1月31日。

主要发现

  • 中位随访13.2年(Q1-Q3: 11.6-14.6年),ICD组294例(52.9%)死亡,对照组299例(53.4%)死亡。
  • ICD未显著降低全因死亡(HR: 0.96; 95% CI: 0.82-1.13)。
  • ICD降低心血管猝死(HR: 0.54; 95% CI: 0.36-0.80)。
  • 年龄对全因死亡效应无交互作用(Pinteraction = 0.89)。
  • 年龄显著修饰ICD对心血管猝死的效应:≤70岁者HR 0.38(95% CI: 0.23-0.62),>70岁者HR 1.27(95% CI: 0.56-2.89;Pinteraction = 0.01)。

关键数值与推荐

  • ICD组全因死亡HR 0.96(95% CI: 0.82-1.13)。
  • ICD组心血管猝死HR 0.54(95% CI: 0.36-0.80)。
  • ≤70岁者心血管猝死HR 0.38(95% CI: 0.23-0.62),>70岁者HR 1.27(95% CI: 0.56-2.89),交互P=0.01。

临床怎么用

  • 对非缺血性HFrEF患者,ICD决策需权衡全因死亡无获益与猝死风险降低。
  • 年龄≤70岁患者可能从ICD降低猝死中获益更多,>70岁者需谨慎评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The most common causes of death may change over time in heart failure with reduced ejection fraction (HFrEF). These shifts can influence the risk-benefit balance of interventions such as implantable cardioverter-defibrillators (ICDs), which are designed to prevent sudden cardiac death. Long-term follow-up is therefore essential to determine whether early benefits are sustained, attenuated, or lost over time. OBJECTIVES: This study sought to examine the long-term effect of primary prevention ICD implantation, compared with usual clinical care, in patients with nonischemic HFrEF enrolled in the DANISH (Danish Study To Assess the Efficacy of ICDs in Patients With Nonischemic Systolic Heart Failure on Mortality) trial. METHODS: The DANISH trial enrolled 1,116 patients with nonischemic HFrEF, left ventricular ejection fraction ≤35%, NYHA functional class II-III (class IV if cardiac resynchronization therapy was planned), and elevated natriuretic peptide levels. The primary outcome was all-cause death, and secondary outcomes were cardiovascular death and sudden cardiovascular death. In this study with extended follow-up, patients were followed until death or January 31, 2024, whichever came first. RESULTS: During a median follow-up of 13.2 years (Q1-Q3: 11.6-14.6 years), 294 patients (52.9%) in the ICD group and 299 (53.4%) in the control group died. Compared with usual clinical care, ICD implantation did not significantly reduce the long-term rate of all-cause death (HR: 0.96; 95% CI: 0.82-1.13), but it did reduce the long-term rate of sudden cardiovascular death (HR: 0.54; 95% CI: 0.36-0.80). The effect of ICD implantation on all-cause death was consistent regardless of age (Pinteraction = 0.89). However, age significantly modified the effect of ICD implantation on sudden cardiovascular death, such that ICD implantation reduced the rate of this outcome in patients ≤70 years (HR: 0.38; 95% CI: 0.23-0.62), but not in those >70 years (HR: 1.27; 95% CI: 0.56-2.89; Pinteraction = 0.01). Similar trends were observed when age was analyzed as a continuous variable. The effect of ICD implantation was generally consistent across other key subgroups, including cardiac resynchronization therapy use at baseline. CONCLUSIONS: In patients with nonischemic HFrEF, during a median follow-up of 13.2 years, primary prevention ICD implantation did not reduce all-cause death, but it did reduce sudden cardiovascular death, and younger individuals appeared to derive a greater benefit. (Danish ICD Study in Patients With Dilated Cardiomyopathy [DANISH]; NCT00542945).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Butt, Doi, Thune, et al. Long-Term Effect of ICDs in Nonischemic Heart Failure With Reduced Ejection Fraction: Extended Follow-Up Analysis of DANISH. J Am Coll Cardiol. 2025. PMID: 41123523. doi:10.1016/j.jacc.2025.08.089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。